Clinical trials
General Population (no Specific Condition or Disease) clinical trials
Below are recruiting general population (no specific condition or disease) clinical trials, each written for real people, not researchers. We’re tracking 10,808 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07732244Recruiting
Testing a wireless brain oxygen monitor in the NICU
This study is testing a new wireless device that monitors oxygen levels in the brain. It is for babies already using a similar wired monitor, to see if the wireless version works just as well.
Montreal, QuebecAges Any age - NCT07731438Recruiting
Calorie restriction and bone marrow fat in obesity and diabetes
This study tests whether a calorie-restricted diet can change the fat in your bone marrow and how it relates to bone health and energy use. It is for premenopausal women and men who are either obese or lean and do not have diabetes.
PragueAges 21–55 - NCT07718061Recruiting
Bacteria in dental plaque with orthodontic retainers
This trial studies the types of bacteria found in dental plaque from people who have orthodontic retainers after braces. It aims to understand how retainers affect oral bacteria.
MurciaAges 18–40 - NCT07613294RecruitingPhase 3
Testing lepodisiran to reduce heart plaque buildup
This study tests whether a new medicine called lepodisiran can shrink plaque in heart arteries for adults with high Lp(a) (a type of cholesterol linked to heart disease) who have had a heart event or are at serious risk. The trial uses CT scans to monitor changes in your arteries.
La Jolla, CaliforniaAges 45–80 - NCT07177339RecruitingPhase 3
Testing depemokimab for COPD with type 2 inflammation
This study tests an early treatment called depemokimab for people with moderate to severe COPD who have a type of inflammation linked to high eosinophils. It aims to reduce flare-ups and improve breathing.
Newport Beach, CaliforniaAges 40–75 - NCT07295847RecruitingPhase 1
Study of AZD0120 for autoimmune diseases
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
Tucson, ArizonaAges 18–75 - NCT07482943RecruitingPhase 4
Dapagliflozin for heart function after Fontan procedure
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
Hong KongAges 12 years+ - NCT07442747RecruitingPhase 2
Aerobic exercise benefits in Parkinson's with DBS
This trial tests whether aerobic exercise (like walking or biking) can improve brain function in people with Parkinson's who have a deep brain stimulation (DBS) device. It may help you learn how exercise affects your symptoms and DBS treatment.
Cleveland, OhioAges 18 years+ - NCT07335263Recruiting
Swaddling or nesting for pain in newborns
This study tests if gently wrapping (swaddling) or positioning (nesting) your baby helps reduce pain and stress while they are on breathing support. It's for newborns who are breathing fast but otherwise healthy.
Merkez, KütahyaAges birth–4 weeks - NCT07453212Enrolling by invitation
Food supplement for dry eye caused by meibomian gland issues
This trial tests a food supplement designed to improve dry eye symptoms by targeting the microbiome. It may help if you have dry eye due to meibomian gland problems and are not using contact lenses or certain other eye treatments.
IstanbulAges 18–65 - NCT07725926Recruiting
Combining therapy techniques for tic-like OCD
This study tests a therapy that combines two approaches—one for tics and one for OCD—to help people whose OCD feels like it's linked to tics. The goal is to see if this combined treatment reduces distressing urges and repetitive behaviors.
London, LondonAges 18–65 - NCT07728695RecruitingPhase 1/Phase 2
Cannabis product for gynecologic pain study
This trial tests a new cannabis-based product to see if it helps with gynecologic pain (like endometriosis). It looks at how the product works and whether it is safe and effective.
Belmont, MassachusettsAges 21 years+ - NCT07107022Recruiting
Study of Penumbra System for acute ischemic stroke
This study is collecting information on how well the Penumbra System works and how safe it is when used to remove blood clots in people having a certain type of stroke. It is for patients who are eligible for mechanical thrombectomy (a procedure to remove the clot) using this device as the first treatment.
Nedlands, Western AustraliaAges 18–80 - NCT06657976RecruitingPhase 2
Beetroot juice and exercise for PAD
This study tests whether beetroot juice, which contains natural nitrates that help blood vessels relax, combined with exercise, can improve walking ability in people with peripheral artery disease (PAD). You might be able to join if you have PAD, can walk without a walker, and are willing to avoid beet products for a while.
Chicago, IllinoisAges 50 years+ - NCT06714006RecruitingPhase 1
Testing safety of PYC-003 for ADPKD
This study is testing a new investigational medicine called PYC-003 for people with autosomal dominant polycystic kidney disease (ADPKD). It is one of the first studies in humans, so the main goal is to see if the medicine is safe and tolerable. The study is for people with a specific genetic cause (PKD1 mutation) and with certain kidney imaging types.
Southport, Gold CoastAges 18–65 - NCT07522099RecruitingPhase 2
Study of ADARx Treatment for Kidney Disease in Chinese Adults
This study tests a new ADARx medicine in Chinese adults with specific types of kidney disease (IgAN, C3G, or IC-MPGN). The goal is to see if this treatment can slow kidney damage and help preserve kidney function.
Shenzhen, GuangdongAges 18 years+ - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07486570Recruiting
Stenting to prevent leaks after colon surgery
This trial tests if placing a small mesh tube (stent) in a major artery can prevent leaks where the colon is reconnected during surgery. It may help people who have a blockage in that artery but no symptoms from it.
Emmen, DrentheAges 40 years+ - NCT06593431RecruitingPhase 3
Treating limited spread pancreatic cancer with local therapy
This trial tests whether combining local treatments (like radiation or surgery) with standard care can help people with pancreatic cancer that has spread to only a few spots (oligometastatic disease). The goal is to improve outcomes for this specific group of patients.
Camden, New JerseyAges 18 years+ - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT05508360Recruiting
Testing an artificial spacer implant for one-level low back pain
This study tests whether inserting a small artificial implant into a single painful disc can reduce long-term low back pain and disability. It’s for people who tried non-surgical treatments for at least 6 months but still have significant symptoms from degenerative disc disease.
Medellín, AntioquiaAges 22 years+ - NCT03610802Recruiting
Send blood samples to study genetic and immune differences
This study collects blood (and sometimes related samples) to learn how genes and the immune system work in people with primary immunodeficiency (PID) or in family members who may not have it. The goal is to improve understanding of rare immune conditions and help guide future care.
Bethesda, MarylandAges 1 day–99 years - NCT07725263Recruiting
Low-dose antifungal for kids with low white blood cells
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent serious fungal infections in children whose immune system is weak after cancer treatment or a stem cell transplant. It's for kids aged 3 to 17 who are at high risk for these infections.
Haikou, HainanAges 3–17 - NCT07724847Recruiting
Validating new criteria for diagnosing axial spondyloarthritis
This study aims to confirm new classification criteria for axial spondyloarthritis, a type of inflammatory arthritis affecting the spine and sacroiliac joints. Participants with chronic back pain lasting at least 3 months and starting before age 45 will undergo a series of tests to see if these new criteria better identify the condition.
Beijing, Beijing MunicipalityAges 18–45
Hear when a new General Population (no Specific Condition or Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for general population (no specific condition or disease)?
- Yes. Clin2 currently lists 10,808 recruiting general population (no specific condition or disease) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a general population (no specific condition or disease) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a general population (no specific condition or disease) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.